Neurobiology of Aging
Volume 30, Issue 9 , Pages 1393-1405 , September 2009

A highly insoluble state of Aβ similar to that of Alzheimer's disease brain is found in Arctic APP transgenic mice

  • Ola Philipson

      Affiliations

    • Department of Public Health and Caring Science, Uppsala University, SE-751 85 Uppsala, Sweden
    • ,
  • Per Hammarström

      Affiliations

    • Department of Chemistry, IFM, Linköping University, SE-581 83 Linköping, Sweden
    • ,
  • K. Peter R. Nilsson

      Affiliations

    • Department of Chemistry, IFM, Linköping University, SE-581 83 Linköping, Sweden
    • UniversitätsSpital Zürich, Institute of Neuropathology, CH-809 Zürich, Switzerland
    • ,
  • Erik Portelius

      Affiliations

    • Department of Neuroscience and Physiology, Sahlgrenska University Hospital, SE-431 80 Mölndal, Sweden
    • ,
  • Tommie Olofsson

      Affiliations

    • Department of Genetics and Pathology, Uppsala University, University Hospital, SE-751 85 Uppsala, Sweden
    • ,
  • Martin Ingelsson

      Affiliations

    • Department of Public Health and Caring Science, Uppsala University, SE-751 85 Uppsala, Sweden
    • ,
  • Bradley T. Hyman

      Affiliations

    • Harvard Medical School, Massachusetts General Hospital, Charlestown, MA 02129, USA
    • ,
  • Kaj Blennow

      Affiliations

    • Department of Neuroscience and Physiology, Sahlgrenska University Hospital, SE-431 80 Mölndal, Sweden
    • ,
  • Lars Lannfelt

      Affiliations

    • Department of Public Health and Caring Science, Uppsala University, SE-751 85 Uppsala, Sweden
    • ,
  • Hannu Kalimo

      Affiliations

    • Department of Genetics and Pathology, Uppsala University, University Hospital, SE-751 85 Uppsala, Sweden
    • Department of Pathology, Helsinki University, University Hospital of Helsinki, FI-00014 Helsinki, Finland
    • ,
  • Lars N.G. Nilsson

      Affiliations

    • Department of Public Health and Caring Science, Uppsala University, SE-751 85 Uppsala, Sweden
    • Corresponding Author InformationCorresponding author at: Public Health and Caring Science/Geriatrics, Rudbeck Laboratory, Dag Hammarskjölds Väg 20, SE-751 85 Uppsala, Sweden. Tel.: +46 18 471 5039; fax: +46 18 471 4808.

Received 16 August 2007 ,Revised 5 October 2007 ,Accepted 19 November 2007.

References 

  1. Bales KR, Verina T, Dodel RC, Du Y, Altstiel L, Bender M, et al. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat. Genet. 1997;17:263–264
  2. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 2000;6:916–919
  3. Basun, H., Bogdanovic, N., Ingelsson, M., Almkvist, O., Näslund, J., Axelman, K., Bird, T.D., Nochlin, D., Schellenberg, G.D., Wahlund, L.-O., Lannfelt, L. Clinical and neuropathological features of the Arctic APP mutation causing early onset Alzheimer's disease. Arch. Neurol., in press.
  4. Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet. 2006;368:387–403
  5. Cheng IH, Palop JJ, Esposito LA, Bien-Ly N, Yan F, Mucke L. Aggressive amyloidosis in mice expressing human amyloid peptides with the Arctic mutation. Nat. Med. 2004;10:1190–1192
  6. Christie RH, Bacskai BJ, Zipfel WR, Williams RM, Kajdasz ST, Webb WW, et al. Growth arrest of individual senile plaques in a model of Alzheimer's disease observed by in vivo multiphoton microscopy. J. Neurosci. 2001;21:858–864
  7. Citron M, Oltersdorf T, Haass C, McConlogue L, Hung AY, Seubert P, et al. Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature. 1992;360:672–674
  8. Crowther DC, Kinghorn KJ, Miranda E, Page R, Curry JA, Duthie FA, et al. Intraneuronal Abeta, non-amyloid aggregates and neurodegeneration in a Drosophila model of Alzheimer's disease. Neuroscience. 2005;132:123–135
  9. DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science. 2002;295:2264–2267
  10. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 2001;98:8850–8855
  11. Ding L, Jonforsen M, Roman L, Andersson M, Inganas O. Photovoltaic cells with a conjugated polyelectrolyte. Synth. Met. 2000;110:133–140
  12. Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, et al. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat. Neurosci. 2002;5:452–457
  13. Englund H, Sehlin D, Johansson AS, Nilsson LN, Gellerfors P, Paulie S, et al. Sensitive ELISA detection of amyloid-beta protofibrils in biological samples. J. Neurochem. 2007;103:334–345
  14. Franklin KBJ, Paxinos G. The Mouse Brain in Stereotaxic Coordinates. Academic Press; 1996;
  15. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, et al Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature. 1995;373:523–527
  16. Gouras GK, Tsai J, Naslund J, Vincent B, Edgar M, Checler F, et al. Intraneuronal Abeta42 accumulation in human brain. Am. J. Pathol. 2000;156:15–20
  17. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353–356
  18. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99–102
  19. Ingelsson M, Fukumoto H, Newell KL, Growdon JH, Hedley-Whyte ET, Frosch MP, et al. Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology. 2004;62:925–931
  20. Jacobsen JS, Reinhart P, Pangalos MN. Current concepts in therapeutic strategies targeting cognitive decline and disease modification in Alzheimer's disease. NeuroRx. 2005;2:612–626
  21. Johansson AS, Berglind-Dehlin F, Karlsson G, Edwards K, Gellerfors P, Lannfelt L. Physiochemical characterization of the Alzheimer's disease-related peptides A beta 1-42Arctic and A beta 1-42wt. FEBS J. 2006;273:2618–2630
  22. Kalback W, Watson MD, Kokjohn TA, Kuo YM, Weiss N, Luehrs DC, et al. APP transgenic mice Tg2576 accumulate Abeta peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer's disease senile plaques. Biochemistry. 2002;41:922–928
  23. Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J. Neurosci. 2001;21:372–381
  24. Kim J, Onstead L, Randle S, Price R, Smithson L, Zwizinski C, et al. Abeta40 inhibits amyloid deposition in vivo. J. Neurosci. 2007;27:627–633
  25. Knobloch M, Konietzko U, Krebs DC, Nitsch RM. Intracellular Abeta and cognitive deficits precede beta-amyloid deposition in transgenic arcAbeta mice. Neurobiol. Aging. 2007;28:1297–1306
  26. Kuo YM, Kokjohn TA, Beach TG, Sue LI, Brune D, Lopez JC, et al. Comparative analysis of amyloid-beta chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer's disease brains. J. Biol. Chem. 2001;276:12991–12998
  27. Laferla FM, Green KN, Oddo S. Intracellular amyloid-beta in Alzheimer's disease. Nat. Rev. Neurosci. 2007;8:499–509
  28. Lannfelt L, Axelman K, Lilius L, Basun H. Genetic counseling in a Swedish Alzheimer family with amyloid precursor protein mutation. Am. J. Hum. Genet. 1995;56:332–335
  29. Levites Y, Smithson LA, Price RW, Dakin RS, Yuan B, Sierks MR, et al. Insights into the mechanisms of action of anti-Abeta antibodies in Alzheimer's disease mouse models. FASEB J. 2006;20:2576–2578
  30. Lord A, Kalimo H, Eckman C, Zhang XQ, Lannfelt L, Nilsson LN. The Arctic Alzheimer mutation facilitates early intraneuronal Abeta aggregation and senile plaque formation in transgenic mice. Neurobiol. Aging. 2006;27:67–77
  31. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and down syndrome. Proc. Natl. Acad. Sci. U.S.A. 1985;82:4245–4249
  32. Matsuoka Y, Saito M, LaFrancois J, Saito M, Gaynor K, Olm V, et al. Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid. J. Neurosci. 2003;23:29–33
  33. McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C, et al. Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron. 2005;47:191–199
  34. Mori H, Takio K, Ogawara M, Selkoe DJ. Mass spectrometry of purified amyloid beta protein in Alzheimer's disease. J. Biol. Chem. 1992;267:17082–17086
  35. Nilsberth C, Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, Forsell C, et al. The ‘Arctic’ APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nat. Neurosci. 2001;4:887–893
  36. Nilsson KP, Herland A, Hammarstrom P, Inganas O. Conjugated polyelectrolytes: conformation-sensitive optical probes for detection of amyloid fibril formation. Biochemistry. 2005;44:3718–3724
  37. Nilsson KP, Hammarstrom P, Ahlgren F, Herland A, Schnell EA, Lindgren M, et al. Conjugated polyelectrolytes-conformation-sensitive optical probes for staining and characterization of amyloid deposits. Chem. Biochem. 2006;7:1096–1104
  38. Nilsson KP, Aslund A, Berg I, Nystrom S, Konradsson P, Herland A, et al. Imaging distinct conformational states of amyloid-beta fibrils in Alzheimer's disease using novel luminescent probes. ACS Chem. Biol. 2007;2:553–560
  39. Nilsson LN, Bales KR, DiCarlo G, Gordon MN, Morgan D, Paul SM, et al. Alpha-1-antichymotrypsin promotes beta-sheet amyloid plaque deposition in a transgenic mouse model of Alzheimer's disease. J. Neurosci. 2001;21:1444–1451
  40. Oddo S, Caccamo A, Smith IF, Green KN, LaFerla FM. A dynamic relationship between intracellular and extracellular pools of Abeta. Am. J. Pathol. 2006;168:184–194
  41. Portelius E, Westman-Brinkmalm A, Zetterberg H, Blennow K. Determination of beta-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry. J. Proteome Res. 2006;5:1010–1016
  42. Roher AE, Lowenson JD, Clarke S, Wolkow C, Wang R, Cotter RJ, et al Structural alterations in the peptide backbone of beta-amyloid core protein may account for its deposition and stability in Alzheimer's disease. J. Biol. Chem. 1993;268:3072–3083
  43. Sahlin C, Lord A, Magnusson K, Englund H, Almeida CG, Greengard P, et al. The Arctic Alzheimer mutation favors intracellular amyloid-beta production by making amyloid precursor protein less available to alpha-secretase. J. Neurochem. 2007;101:854–862
  44. Saido TC, Yamao-Harigaya W, Iwatsubo T, Kawashima S. Amino- and carboxyl-terminal heterogeneity of beta-amyloid peptides deposited in human brain. Neurosci. Lett. 1996;215:173–176
  45. Saido TC, Iwatsubo T, Mann DM, Shimada H, Ihara Y, Kawashima S. Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques. Neuron. 1995;14:457–466
  46. Schoonenboom NS, Mulder C, Van Kamp GJ, Mehta SP, Scheltens P, Blankenstein MA, et al. Amyloid beta 38, 40, and 42 species in cerebrospinal fluid: more of the same?. Ann. Neurol. 2005;58:139–142
  47. Solomon B, Koppel R, Frankel D, Hanan-Aharon E. Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc. Natl. Acad. Sci. U.S.A. 1997;94:4109–4112
  48. Stenh C, Englund H, Lord A, Johansson AS, Almeida CG, Gellerfors P, et al. Amyloid-beta oligomers are inefficiently measured by enzyme-linked immunosorbent assay. Ann. Neurol. 2005;58:147–150
  49. Westman AK, Wei LY, Barre F. Preparation for TEM of layered samples with fragile microstructure and weak layer interface. Microsc. Res. Tech. 1999;45:198–202
  50. Wilcock DM, Rojiani A, Rosenthal A, Levkowitz G, Subbarao S, Alamed J, et al. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J. Neurosci. 2004;24:6144–6151
  51. Wirths O, Multhaup G, Czech C, Blanchard V, Moussaoui S, Tremp G, et al. Intraneuronal Abeta accumulation precedes plaque formation in beta-amyloid precursor protein and presenilin-1 double-transgenic mice. Neurosci. Lett. 2001;306:116–120
  52. Wyss-Coray T, Masliah E, Mallory M, McConlogue L, Johnson-Wood K, Lin C, et al. Amyloidogenic role of cytokine TGF-beta1 in transgenic mice and in Alzheimer's disease. Nature. 1997;389:603–606
  53. Yamamoto M, Horiba M, Buescher JL, Huang D, Gendelman HE, Ransohoff RM, et al. Overexpression of monocyte chemotactic protein-1/CCL2 in beta-amyloid precursor protein transgenic mice show accelerated diffuse beta-amyloid deposition. Am. J. Pathol. 2005;166:1475–1485

PII: S0197-4580(07)00455-1

doi: 10.1016/j.neurobiolaging.2007.11.022

Neurobiology of Aging
Volume 30, Issue 9 , Pages 1393-1405 , September 2009

Article Tools

* Image Usage & Resolution